Table 2.

BsAbs under clinical development in China by Chinese companies as of May 2020 [78]

Identifier	Drug	Company	Targets	BsAb format and platform	Indication	Phase
CTR20171194	M802	YZYBio	HER2 × CD3	scFv-Fab IgG; YBODY	HER2-positive advanced solid tumor	I
CTR20181212	M701	YZYBio	EpCAM × CD3	scFv-Fab IgG; YBODY	Malignant ascites	I
CTR20182027	AK104	Akeso	PD-1 × CTLA-4	IgG-(scFv)2; Tetrabody	Advanced solid tumor and advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma	Ib/II
CTR20190205	A-319	Generon	CD19 × CD3	(scFv)2-Fab; ITAB	Refractory or relapsed B cell lymphoma	I
CTR20190853	KN026	Alphamab	HER2 × HER2	Hetero H, common LC IgG; CRIB	Advanced gastric and gastroesophageal junction carcinoma with overexpression and low expression of HER2	II
CTR20182404	SHR-1701	Hengrui	PDL1 × TGFβ	Antibody-receptor fusion	Metastatic castration resistant prostate cancer	I
CTR20181823		Advanced malignant solid tumor
CTR20181760	MBS301	Mabworks	HER2 × HER2	Fab-arm exchange	HER2 high expression of locally advanced, inflammatory or early breast cancer, metastatic breast cancer, metastatic gastric cancer, etc.	I
CTR20190427	KN046	Alphamab	PD-L1 × CTLA-4	Hetero VHH-Fc; CRIB	Advanced unresectable or metastatic esophageal squamous cell carcinoma	II
CTR20190197					Triple negative breast cancer	II
CTR20190195					Non-small-cell lung cancer	II
CTR20181996					Chinese advanced solid tumor and lymphoma subjects	I
CTR20190241	EMB-01	Epimab	EGFR × c-MET	F(ab)2-IgG; FIT-Ig	Advanced/metastatic solid tumors, including but not limited to non-small-cell lung cancer, colorectal cancer (no RAS-positive mutation), gastric cancer, liver cancer, and other solid tumors	I
CTR20190340	IBI318	Innovent	PD-1 × PD-L1	Fab-arm exchange	Advanced malignant tumor	I
CTR20190888	ES101	Elpiscience	PD-L1 × CD137	Tandem VHH-Fc	Advanced solid tumor	I
CTR20191955	K193	Lvzhu	CD19 × CD3	F(ab)2-(scFv)2-Fc	B-cell lymphoma	I
CTR20191677	IBI315	Innovent	HER2 × PD-1	Fab-arm exchange	Advanced malignant tumor	I
CTR20192612	IMM0306	ImmuneOnco	CD47 × CD20	Antibody-receptor fusion	Lymphoma	I
CTR20192299	HX009	HanxBio	CD47 × PD-1	Antibody-receptor fusion	Malignant tumors such as liver cancer, stomach cancer, and colorectal cancer	I
CTR20200502	SI-B001	Biokin	HER3 × EGFR	IgG-(scFv)2	Locally advanced or metastatic epithelial tumor, including esophageal squamous cell carcinoma, lung squamous cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, colorectal cancer, etc.	I
CTR20200175	IBI322	Innovent	PD-L1 × CD47	Not available	Solid tumors and hematological tumors	I
CTR20200549	MGD013	ZLAB	PD-1 × LAG-3	DART	Advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma)	I
CTR20200289					Advanced gastric adenocarcinoma or adenocarcinoma at the gastroesophageal junction with previous treatment failed	I
CXSL1900112	SI-B003	Biokin	Undisclosed	Not available	Undisclosed	IND
CXSL1900131	KD6001	Kanda	Undisclosed	Not available	Advanced malignant tumor	IND
CXSL1900150	PM8001	Biotheus	Undisclosed	Not available	Advanced solid tumor	I